Efficacy and safety of tolvaptan in patients with severe aortic stenosis and chronic kidney disease undergoing transcatheter aortic valve replacement
Not Applicable
Recruiting
- Conditions
- aortic valve stenosis, chronic kidney disease
- Registration Number
- JPRN-UMIN000033577
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who violate the following criteria are excluded from this study 1 Patients receiving hemodialysis therapy 2 patients already taking tolvaptan 3 Patients with difficult oral medication 4 Patients who do not feel dry mouth 5 Those whose serum sodium level measured within 24 hours before the start of the study drug exceeds 150 mEq / ml 6 In addition, patients whose research managers judged inappropriate as subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method